You are here

EPIC

Ponatinib in Newly Diagnosed CML
Recruitment period: 
1 June 2012 to 1 October 2013
Trial period: 
1 June 2012 to 1 October 2013
Clinical Trial reference link: 
NCT01650805

Treatments:

For newly diagnosed patients: 
no

This study has been terminated

(Study terminated based on evaluation of safety data)

Sponsor: Ariad Pharmaceuticals
Information provided by (Responsible Party): Ariad Pharmaceuticals
First received: July 18, 2012
Last updated: October 18, 2013
Last verified: October 2013

This multicenter, international,Phase 3 Randomized, Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase